Literature DB >> 31221701

Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes.

Fernando Bril1,2, Diana Julie Leeming3, Morten Asser Karsdal3, Srilaxmi Kalavalapalli1, Diana Barb1, Jinping Lai4, Matthew Rabe1, Kenneth Cusi5,2.   

Abstract

OBJECTIVE: This study assessed the utility of plasma fragments of propeptides of type III (PRO-C3), V (PRO-C5), and VI (PRO-C6) procollagen for the detection of liver fibrosis in patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: Patients with T2DM (n = 191) underwent an oral glucose tolerance test, a liver 1H-MRS, and a liver biopsy when indicated. PRO-C3, PRO-C5, and PRO-C6 were blindly assessed.
RESULTS: PRO-C3 performed well for the diagnosis of moderate-to-advanced (area under the receiver operating characteristic curve [AUROC] 0.81 [95% CI 0.74-0.88]) and advanced (AUROC 0.88 [0.80-0.95]) fibrosis in T2DM patients. Its performance was similar to that of AST to platelet ratio index (APRI) (AUROC 0.83 and 0.87, respectively) and Fibrosis-4 (FIB-4) (AUROCs 0.83 and 0.86, respectively) scores. Use of PRO-C5 and PRO-C6 did not improve the accuracy to detect liver fibrosis. After 18 months, PRO-C3 changes were associated with changes in fibrosis stages.
CONCLUSIONS: PRO-C3 performed well for the detection of fibrosis in T2DM patients and showed promising results for prediction of histological changes in fibrosis stage with treatment.
© 2019 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31221701     DOI: 10.2337/dc18-2578

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  11 in total

1.  Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosis.

Authors:  Elisabeth Erhardtsen; Daniel G K Rasmussen; Peder Frederiksen; Diana Julie Leeming; Diane Shevell; Lise Lotte Gluud; Morten Asser Karsdal; Guruprasad P Aithal; Jörn M Schattenberg
Journal:  JHEP Rep       Date:  2021-07-10

2.  PRO-C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD.

Authors:  Catherine C Cohen; Eduardo Castillo-Leon; Alton B Farris; Shelley A Caltharp; Rebecca L Cleeton; Elizabeth M Sinclair; Diane E Shevell; Morten A Karsdal; Mette Juul Fisker Nielsen; Diana J Leeming; Miriam B Vos
Journal:  Hepatol Commun       Date:  2021-07-08

3.  Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.

Authors:  Rajaa Nahra; Tao Wang; Kishore M Gadde; Jan Oscarsson; Michael Stumvoll; Lutz Jermutus; Boaz Hirshberg; Philip Ambery
Journal:  Diabetes Care       Date:  2021-05-20       Impact factor: 17.152

Review 4.  Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis.

Authors:  Chien-Yu Lin; Pratik Adhikary; Kun Cheng
Journal:  Adv Drug Deliv Rev       Date:  2021-04-20       Impact factor: 17.873

Review 5.  Metabolic liver disease in diabetes - From mechanisms to clinical trials.

Authors:  Bedair Dewidar; Sabine Kahl; Kalliopi Pafili; Michael Roden
Journal:  Metabolism       Date:  2020-06-20       Impact factor: 8.694

6.  Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease.

Authors:  Stephen A Harrison; Seth J Baum; Nadege T Gunn; Ziad H Younes; Anita Kohli; Rashmee Patil; Margaret J Koziel; Harinder Chera; Jeff Zhao; Manu V Chakravarthy
Journal:  Am J Gastroenterol       Date:  2021-12-01       Impact factor: 12.045

7.  Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease.

Authors:  Angelo Armandi; Chiara Rosso; Aurora Nicolosi; Gian Paolo Caviglia; Maria Lorena Abate; Antonella Olivero; Daphne D'Amato; Marta Vernero; Melania Gaggini; Giorgio Maria Saracco; Davide Giuseppe Ribaldone; Diana Julie Leeming; Amalia Gastaldelli; Elisabetta Bugianesi
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

8.  A Simple Test to Identify the Risk of NASH and Cirrhosis in People With Obesity or Diabetes: The Time to Screen Is Now.

Authors:  Kenneth Cusi
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

9.  Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.

Authors:  Mark L Hartman; Arun J Sanyal; Rohit Loomba; Jonathan M Wilson; Amir Nikooienejad; Ross Bray; Chrisanthi A Karanikas; Kevin L Duffin; Deborah A Robins; Axel Haupt
Journal:  Diabetes Care       Date:  2020-04-14       Impact factor: 19.112

Review 10.  Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Anne Linde Mak; Jenny Lee; Anne-Marieke van Dijk; Yasaman Vali; Guruprasad P Aithal; Jörn M Schattenberg; Quentin M Anstee; M Julia Brosnan; Mohammad Hadi Zafarmand; Dewkoemar Ramsoekh; Stephen A Harrison; Max Nieuwdorp; Patrick M Bossuyt; Adriaan G Holleboom
Journal:  Biomedicines       Date:  2021-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.